Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innoviva, Inc. filings document a Nasdaq-listed common-stock issuer with a royalty healthcare portfolio, Innoviva Specialty Therapeutics operations, and strategic healthcare investments. Form 8-K reports furnish operating results and financial condition, including royalty revenue, IST net product sales, product-portfolio developments, fair-value changes in investments, and capital allocation activity.
Proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, and equity incentive plan approvals. The record also identifies the company’s common stock, par value $0.01 per share, traded under INVA on the Nasdaq Global Select Market.
Innoviva, Inc. reported that Chief Accounting Officer Marianne Zhen acquired equity awards as compensation. She was conditionally granted 12,766 time-vested restricted stock units and 31,500 non-statutory stock options with an exercise price of $22.99 per share, each for Innoviva common stock.
The awards are subject to stockholder approval of Innoviva's 2026 Equity Incentive Plan at the 2026 annual meeting on May 4, 2026. Twenty-five percent of both the RSUs and options vest on February 20, 2027, with the remainder vesting in twelve equal quarterly installments, subject to continued service and certain change-in-control and involuntary termination provisions. Following the grant, Zhen directly holds 58,643 common shares and 31,500 options.
Innoviva, Inc. director Sarah J. Schlesinger received new equity compensation awards. She was granted 9,786 shares of common stock in the form of restricted stock units and a non-statutory stock option for 10,000 shares at an exercise price of $22.99 per share.
These grants were made following Innoviva’s 2026 annual meeting of stockholders and are compensation awards, not open-market purchases. All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the grant, contingent on her continued service as an Outside Director, with accelerated vesting upon death, disability, or a qualifying change in control under the 2026 Equity Incentive Plan.
After these awards, she directly holds 140,492 shares of common stock and 10,000 options.
Innoviva, Inc. reported that its Chief Financial Officer, Stephen Basso, received equity-based compensation awards. He was granted 37,994 time-vested restricted stock units of common stock and a non-statutory stock option for 93,750 shares at an exercise price of $22.99 per share.
These RSUs and options were conditionally granted under Innoviva's 2026 Equity Incentive Plan, subject to stockholder approval at the 2026 annual meeting on May 4, 2026. Twenty-five percent of each award vests on February 20, 2027, with the remaining portions vesting in twelve equal quarterly installments, assuming continued service.
The vesting schedule includes potential accelerated vesting in certain change in control and involuntary termination scenarios as defined in the 2026 Equity Incentive Plan. Following the RSU grant, Basso directly holds 88,007 shares of Innoviva common stock.
Innoviva, Inc. director Derek A. Small received equity awards tied to his board service. He acquired 9,786 shares of common stock through restricted stock units at no cost and now holds 45,035 shares directly. He was also granted non-statutory stock options for 10,000 shares of common stock at an exercise price of $22.99 per share, expiring in 2036. All RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of grant, with accelerated vesting upon death, disability, or certain change in control events.
Haimovitz Jules reported acquisition or exercise transactions in this Form 4 filing.
Innoviva, Inc. director Jules Haimovitz received equity compensation in the form of restricted stock units and stock options. He was granted 9,786 shares of Common Stock as RSUs and 10,000 non-statutory stock options, each option exercisable at $22.9900 per share.
All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the May 4, 2026 grant, subject to his continuous service as an Outside Director. Vesting accelerates upon death, disability, or a qualifying change in control under Innoviva’s 2026 Equity Incentive Plan. Following the stock award, Haimovitz directly holds 152,692 shares of Common Stock and 10,000 options.
Innoviva, Inc. reported results from its Annual Meeting of Stockholders held on May 4, 2026. Stockholders elected five directors for one-year terms ending at the 2027 annual meeting, including Chief Executive Officer Pavel Raifeld, with each nominee receiving a strong majority of votes cast.
Stockholders approved, on a non-binding advisory basis, Innoviva’s executive compensation and ratified the Audit Committee’s selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved Innoviva’s 2026 Equity Incentive Plan, supporting the company’s ongoing compensation and governance framework.
Innoviva Inc filing shows Vanguard Portfolio Management reports beneficial ownership of 4,288,063 shares of common stock, representing 5.79% of the class. The filing lists 63,112 shares as sole voting power and 4,288,063 as sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Innoviva, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025. The amendment is made to comply with Rule 3-09 of Regulation S-X and updates the exhibits section to add separate financial information for an equity investee.
The filing includes the Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. as of December 31, 2025 and 2024 and for the years then ended, along with the related consent from Armata’s independent registered public accounting firm, Ernst & Young LLP. It also provides new certifications from Innoviva’s principal executive and principal financial officers.
The amendment states that, apart from these added exhibits and certifications, all disclosures remain unchanged from the original Annual Report. As of June 30, 2025, the aggregate market value of Innoviva’s common equity held by non‑affiliates was $1.26 billion, and on February 13, 2026, 74,073,646 shares of common stock were outstanding.
Innoviva Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating that, following an internal realignment on January 12, 2026, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing reports 0 shares beneficially owned (0% of the class) of Innoviva common stock. The filing lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration dated 03/27/2026.
Innoviva, Inc. is asking stockholders to vote at its May 4, 2026 annual meeting on corporate governance, pay, auditors and a major new equity plan. Investors will elect five directors, cast an advisory Say-On-Pay vote and consider ratifying Deloitte & Touche LLP as auditor for 2026.
A key item is approval of the 2026 Equity Incentive Plan, reserving 9,000,000 shares of common stock, about 10% of fully diluted shares as of March 9, 2026, to support future stock-based compensation and contingent grants to executives and employees. The proxy highlights strong 2025 results, including net income of $3.30 per diluted share, roughly $645 million in cash and receivables, over $75 million invested in healthcare opportunities and a new $125 million share repurchase program.